Summary
β-Adrenoceptor density and β1- and β2-subtype distribution were examined in hippocampi and cerebella from patients with Alzheimer's disease (AD/SDAT). Tissues from age-, sex and post-mortem delay matched non-demented patients served as controls. The total β-adrenoceptor density as evaluated in saturation experiments with the hydrophilic radioligand [3H]CGP 12177 was higher in hippocampal (36–39 fmol/mg protein) than cerebellar tissues (20–21 fmol/mg), however, no differences were found in either brain region between AD/SDAT patients and controls. Subtype distribution using the highly selective β1-adrenoceptor antagonist CGP 20712A revealed a slightly higher proportion of β1-adrenoceptors in hippocampus (26%–27%) than in cerebellum (20%–21%) with, again, no difference between AD/SDAT and controls. We recently described a 40% reduction in basal and stimulated adenylyl cyclase activity in post-mortem hippocampus of AD/SDAT patients, a brain region greatly affected by the disease, the present data now demonstrate that this disease-related effect is not mirrored by a similar change in β-adrenoceptor density nor in subtype distribution.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ackermann H (1991) BIAS — Biometrische Analyse von Stichproben. Version 2.1. Prisma Verlagsdruckerei, Frankfurt/M
Biegon A (1991) Acetylcholine, serotonin and β-adrenoceptors. In: Mendelsohn FAO, Paxinos G (eds) Receptors in the human nervous system. Academic Press, San Diego, pp 49–69
Bowen DM, Allen SJ, Benton JS, Goodhart MJ, Haan EA, Palmer AN, Sims NR, Smith CCT, Spillane JA, Esiri MM, Neary D, Snowdon JS, Wilcock JK, Davison AN (1983) Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease. J Neurochem 41:266–272
Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259
Cheng Y-C, Prusoff WH (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108
Cooper JK (1991) Drug treatment of Alzheimer's disease. Arch Intern Med 151:245–249
Cross AJ, Crow TJ, Ferrier IN, Johnson JA, Bloom SR, Corsellis JAN (1984a) Serotonin receptor changes in dementia of the Alzheimer type. J Neurochem 43:1574–1581
Cross AJ, Crow TJ, Johnson JA, Perry EK, Perry RH, Blessed G, Tomlinson BE (1984b) Studies on neurotransmitter receptor systems in neocortex and hippocampus in senile dementia of the Alzheimer type. J Neurol Sci 64:109–117
De Paermentier F, Cheetham SC, Crompton RC, Horton RW (1989). β-Adrenoceptors in human brain labelles with [3H]dihydroalprenolol and [3H]CGP 12177. Eur J Pharmacol 167:397–405
Dickinson KEJ, Nahorski SR (1981) Identification of solubilised beta, and beta2 adrenoceptors in mammalian lung. Life Sci 29: 2527–2533
Dooley DJ, Bittiger H (1987) Quantitative assessment of central β1-and β2-adrenoceptor regulation using CGP 20712A. J Pharmacol Meth 18:131–136
Dooley DJ, Bittiger H, Reymann NC (1986) CGP 20712A: a useful tool for quantitating β1- and β2-adrenoceptors. Eur J Pharmacol 130:137–139
Hoyer S (1990) Changes in brain energy metabolism and the early detection of Alzheimer's disease. In: Dostert P, Riederer P, Benedetti MS, Roncucci R (eds) Early markers in Parkinson's and Alzheimer's diseases, Springer, Wien New York, pp 233–244
Jagust WJ, Seab SP, Huesman RH, Valk PE, Mathis CA, Reed BR, Coxson PG, Budinger TF (1991) Diminished glucose transport in Alzheimer's disease: dynamic PET studies. J Cereb Blood Flow Metab 11:323–330
Jenni-Eiermann S, von Hahn HP, Honegger CG, Ulrich J (1984) Studies on neurotransmitter binding in senile dementia. Gerontology 30:350–358
Kalaria RN, Andorn AC, Tabaton M, Whitehouse PJ, Harik SI, Unnerstall JR (1989) Adrenergic receptors in aging and Alzheimer's disease: increased β2-receptors in prefrontal cortex and hippocampus. J Neurochem 53:1772–1781
Khatchaturian ZS (1985) Diagnosis of Alzheimer's disease. Arch Neurol 42:1097–1105
Kumar A, Calache M (1991) Treatment of Alzheimer's disease with cholinergic drugs. Int J Clin Pharmacol Ther Toxicol 29:23–37
Kumar A, Schapiro MB, Haxby JV, Grady CL, Friedland RP (1990) Cerebral metabolic and cognitive studies in dementia with frontal lobe behavioral features. J Psychiatr Res 24:97–109
Lemmer B, Schmitt M, Bohl J, Ohm T (1990a) Dose-dependent adenylate cyclase stimulation by a water soluble forskolin in postmortem hippocampus of control and AD/SDAT patients. Naunyn-Schmiedeberg's Arch Pharmacol 341:R94
Lemmer B, Schmitt M, Gottheiner H, Ohm T, Bohl J (1990b) Zur Beta-Adrenozeptor-cAMP-vermittelten Signalübertragung im Hippocampus von Alzheimer Patienten: Dissoziation zwischen Veränderungen der β-Rezeptoren und der Adenylatzyklase. 8. Arbeitstagung der Anatomischen Gesellschaft, Abstract 36
Lemmer B, Langer L, Ohm T, Bohl J (1992) Beta-adrenoceptor subtypes in cerebellum and hippocampus of Alzheimer patients and non-demented controls (abstract). Naunyn-Schmiedeberg's Arch Pharmacol 345:R121
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265–275
Mattes A, Witte K, Hohmann W, Lemmer B (1991) PHARMFIT — a nonlinear fitting program for pharmacology. Chronobiol Int 8:460–476
McLaughlin M, Ross BM, Milligan G, McCulloch J, Knowler JT (1991) Robustness of G proteins in Alzheimer's disease: an immunoblot study. J Neurochem 57:9–14
Ohm TG, Schmitt M, Lemmer B, Bohl J (1990) Regionale Unterschiede der cAMP-vermittelten Signalübertragungsstorung im Hirngewebe des Menschen bei der Demenz vom Alzheimer Typ. 8. Arbeitstagung der Deutschen Gesellschaft für Anatomie, Abstract 15
Ohm TG, Bohl J, Lemmer B (1991) Reduced basal and stimulated (isoprenaline, Gpp(NH)p and forskolin) adenylate cyclase activity in Alzheimer's disease correlated with histopathological changes. Brain Res 540:229–236
Perry EK, Smith CJ, Court JA, Perry RH (1990) Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types. J Neural Transm (P-D Sect)2:149–158
Quirion R, Aubert I, Lapchak PA, Schaum RP, Teolis S, Gauthier S, Araujo DM (1989) Muscarinic receptor subtypes in human neurodegenerative disorders: focus on Alzheimer's disease. TIPS 10(Suppl):80–84
Shimohama S, Taniguchi T, Fujiwara M, Kameyama M (1987) Changes in β-adrenergic receptor subtypes in Alzheimer-type dementia. J Neurochem 48:1215–1221
Shimohama S, Homma Y, Suenaga T, Fujimoto S, Taniguchi T, Araki W, Yamaoka Y, Takenawa T, Kimura J (1991) Aberrant accumulation of phospholipase c-delta in Alzheimer brains. Am J Pathol 139:737–742
Stiles GL, Taylor S, Lefkowitz RJ (1983) Human cardiac beta adrenergic receptors: suptype heterogeneity delineated by direct radioligand binding. Life Sci 33:467–473
Author information
Authors and Affiliations
Additional information
Correspondence to B. Lemmer
Rights and permissions
About this article
Cite this article
Lemmer, B., Langer, L., Ohm, T. et al. Beta-adrenoceptor density and subtype distribution in cerebellum and hippocampus from patients with Alzheimer's disease. Naunyn-Schmiedeberg's Arch Pharmacol 347, 214–219 (1993). https://doi.org/10.1007/BF00169270
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00169270